Delayed vaccine-induced CD8⁺ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication.

"Competing interests: This study has been conducted by LUMC, which holds a patent on the use of synthetic long peptides as vaccine (US 7.202.034). CJMM and SHvdB are named as inventors on this patent. Additionally, the LUMC holds a patent on the use of T cell cycle synchronization to optimize antitumor responses (No2019548). SHvdB, RA, CJMM and TCvdS are named inventors on this patent. CJMM is employed full time by ISA Pharmaceuticals, which exploits the long-peptide vaccine patent, and has been granted options on ISA Pharmaceuticals stock. SHvdB is a member of the Scientific Advisory Board and receives consultancy fees from ISA Pharmaceuticals. RA is a member of the Scientific Advisory Board of QIAGEN."

"Funding: This work was supported by grants from the Dutch Cancer Society (KWF 4400 to CJMM and SHvdB, KWF 11750 to RA) and a Gisela Thier grant from LUMC to TCvdS."